Article Text

Download PDFPDF
Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times

Footnotes

  • Contributors SF and PSM have both designed the study, acquired the data, analysed the data, written the article and approved the final version.

  • Competing interests SF reports grants and personal fees from Novartis, grants and personal fees from Bayer, personal fees from Quantel, outside the submitted work; PSM reports personal fees from Novartis, personal fees from Bayer, personal fees from Heidelberg Engineering, outside the submitted work.

  • Ethics approval Ethics committee of the University of Cologne (reference number 11-027).

  • Provenance and peer review Not commissioned; externally peer reviewed.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors SF and PSM have both designed the study, acquired the data, analysed the data, written the article and approved the final version.

  • Competing interests SF reports grants and personal fees from Novartis, grants and personal fees from Bayer, personal fees from Quantel, outside the submitted work; PSM reports personal fees from Novartis, personal fees from Bayer, personal fees from Heidelberg Engineering, outside the submitted work.

  • Ethics approval Ethics committee of the University of Cologne (reference number 11-027).

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Keith Barton James Chodosh Jost Jonas